The drive for transplant diagnostics has stemmed from the vast unmet need for precision diagnostics to increase the life of transplant patients. These diagnostics among other things help in the longevity of the transplanted organ by reducing factors that can lead to acute injection and monitor noncompliance as early as possible. This is imperative for the management of rejection episodes. Graft rejection may be caused by antibodies whose identification has been facilitated advances in molecular diagnostics.
Get Sample Copy of this Report @
Advances in Molecular Biomarkers Expand Potential
The adoption of better transcriptomic, proteomic, and genomic biomarkers has paved way for cutting-edge research in transplant diagnostics. In particular, this has helped reduce allograft injury. This is especially noticeable in liver and kidney patients. The integration of molecular technologies with histopathology and sensitive antibody testing has led to led to the availability of more precise transplant diagnostics.
Growing demand for personalized management of the transplanted organ is also offering marked momentum to the evolution of the transplant diagnostics. Better transplant diagnostics should also enable clinicians in identifying different causes of transplant rejection. Implementation of recommendations in numerous countries on increasing the organ donor rate has also bolstered the demand for transplant diagnostics. Collaborative efforts of governments in these countries have helped propel the need for transplant diagnostics.
Read Comprehensive Overview of Report @
Research on Faster Translation of Novel Tools Boosting Market
Among the various regions, North America and Europe are prominent market, growing on the back of rising investments in the discovery of new diagnostic tools. Robust research for faster translation of these tools to clinical venue in the key economies of North America has pivoted the expansion of the regional market. Initiatives taken by the healthcare industries in these nations to address challenge in increasing the longevity of transplant diagnostics is also boosting the market. These developed markets are witnessing the advent of techniques that allow multiple targets of transplant rejection to be identified simultaneously.